Stock CUE CUE BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Real-time Estimate Cboe BZX
Other stock markets
 02:34:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
2.21 USD +3.76% Intraday chart for Cue Biopharma, Inc. +55.63% -16.29%
Apr. 08 Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
Apr. 08 North American Morning Briefing : Inflation Data, -2- DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
GL
North American Morning Briefing : Inflation Data, -2-
DJ
Cue Biopharma to Host Business Update Call and Webcast
GL
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Tech in Focus on -2-
DJ
North American Morning Briefing : Investors -2-
DJ
Jefferies Starts Cue Biopharma With Buy Rating
MT
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
GL
Transcript : Cue Biopharma, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
GL
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
GL
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
AQ
Piper Sandler Adjusts Price Target on Cue Biopharma to $8 From $7, Maintains Overweight Rating
MT
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CUE Stock
  4. News Cue Biopharma, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW